A recent study has identified that specific variations in a single gene, known as APOE, may be responsible for more than 90% of all Alzheimer’s disease cases. This groundbreaking research suggests that focusing on treatments targeting this gene could potentially prevent the onset of the disease in the vast majority of individuals.
Researchers from University College London (UCL) conducted a comprehensive analysis of the three primary variations of the APOE gene: ε2, ε3, and ε4. The ε2 variant is associated with a protective effect against cognitive decline, while the ε4 variant is known to significantly increase the risk of developing Alzheimer’s. The ε3 variant, historically viewed as neutral, has been re-evaluated and found to play a crucial role in disease risk.
According to the findings, based on genetic data from nearly 470,000 people, ε3 should no longer be considered neutral. Rather, it is a major risk factor for Alzheimer’s disease. Dylan Williams, a genetic epidemiologist at UCL, emphasized, “When we consider the contributions of ε3 and ε4, we can see that APOE potentially has a role in almost all Alzheimer’s disease.”
Individuals inherit two copies of the APOE gene, one from each parent, leading to six possible combinations. The most protective combination is ε2/ε2, while ε4/ε4 presents the highest risk. Most people fall somewhere in between, depending on their inherited combinations. These combinations significantly affect the structure and function of the proteins produced, which in turn influence various brain activities linked to Alzheimer’s, such as neuron repair and inflammation control.
The research team proposes that interventions targeting the APOE gene or its protein products could significantly reduce the risk of Alzheimer’s, potentially lowering many individuals to the risk level associated with the ε2/ε2 combination. Williams remarked, “Intervening on the APOE gene specifically, or the molecular pathway between the gene and the disease, could have great, and probably under-appreciated, potential for preventing or treating a large majority of Alzheimer’s disease.”
The implications of this research extend beyond Alzheimer’s, as almost half of all dementia cases may also be attributed to variations in the APOE gene. While genetic factors play a critical role, the study highlights that these genetic risks do not exist in isolation. Environmental and lifestyle factors, such as obesity, social isolation, and sleep deprivation, may compound the genetic risks, although the precise interactions remain unclear.
Williams noted, “Without the contributions of APOE ε3 and ε4, most Alzheimer’s disease cases would not occur, irrespective of what other factors are inherited or experienced.” This underscores the need for further investigation into the APOE gene’s role in Alzheimer’s and dementia.
Despite the promising findings, targeting genes and proteins for treatment poses significant challenges. Any gene therapy must be conducted with rigorous control and assessment. Nonetheless, these discoveries could signal a shift in Alzheimer’s research, which has struggled to find effective treatment options.
Williams concluded, “With complex diseases like Alzheimer’s and other diseases that cause dementia, there will be more than one way to reduce disease occurrence. We should explore various options to modify Alzheimer’s and dementia risk, including but not limited to strategies related to APOE.”
The full study has been published in the journal NPJ Dementia, marking a significant contribution to the ongoing battle against Alzheimer’s disease.
